Peptimmune Picks Up $8.9M

Peptimmune has finished an $8.9 million second close of its Series D financing, the Cambridge, MA-based firm announced today. The funding, led by New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, and Silicon Valley Bank Capital, will be used to further development of Peptimmune’s treatment for multiple sclerosis.

Rebecca is Xconomy's co-founder. Follow @

Trending on Xconomy